Pharmacokinetic variability of beta‐adrenergic blocking agents used in cardiology

DOI Web Site Web Site Web Site Web Site 被引用文献2件
  • Frederik N. Ågesen
    Department of Cardiology University of Copenhagen Rigshospitalet, Copenhagen Denmark
  • Peter E. Weeke
    Department of Cardiology University of Copenhagen Rigshospitalet, Copenhagen Denmark
  • Peer Tfelt‐Hansen
    Danish Headache Center, Department of Neurology University of Copenhagen, Rigshospitalet‐Glostrup Hospital Glostrup Denmark
  • Jacob Tfelt‐Hansen
    Department of Cardiology University of Copenhagen Rigshospitalet, Copenhagen Denmark

書誌事項

公開日
2019-07-12
権利情報
  • http://creativecommons.org/licenses/by/4.0/
DOI
  • 10.1002/prp2.496
公開者
Wiley

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>The aim of this study was to evaluate the pharmacokinetic variability of beta‐adrenergic blocking agents used in cardiology by reviewing single‐dose and steady‐state pharmacokinetic studies from the literature. PubMed was searched for pharmacokinetic studies of beta‐adrenergic blocking agents, both single‐dose and steady‐state studies. The studies included reported maximum plasma concentration (C<jats:sub>max</jats:sub>) and/or area under the concentration curve (AUC). The coefficient of variation (CV%) was calculated for all studies, and a CV% <40% was considered low or moderate variability, and a CV% >40% was considered high variability. The C<jats:sub>max</jats:sub> and AUC were reported a total of 672 times in 192 papers. Based on AUC, metoprolol, propranolol, carvedilol, and nebivolol showed high pharmacokinetic variability (highest first), whereas bisoprolol, atenolol, sotalol, labetalol, nadolol, and pindolol showed low to moderate variability (lowest first). We have shown a high interindividual pharmacokinetic variability that varies markedly in different beta‐adrenergic blocking agents; the extreme being steady state ratios as high as 30 in metoprolol. A more personalized approach to the medical treatment of patients may be obtained by combining known pharmacokinetic information about variability, pharmaco‐genetics and ‐dynamics, and patient characteristics, to avoid adverse events or lack of treatment effect.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

問題の指摘

ページトップへ